In regard to the direct causality limitation, CRISPR-based validation of key regulatory relationships could establish causality in the Top2b network, while in another sense, pharmacological studies targeting Top2b modulation could assess potential therapeutic benefits in retinal degeneration models. Here, TOP2B is linked to retinal degeneration.